ORIGINAL ARTICLE
Transforming Growth Factor Beta-1 in Human Colorectal Cancer Patients
 
More details
Hide details
1
Yuzuncu Yıl University Medical Faculty, Van, Turkey
2
İstanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey
3
Okmeydanı Training Hospital, Department of Endocrinology, Istanbul, Turkey
4
Haseki Training Hospital, II. General Surgery, Istanbul, Turkey
Publish date: 2011-01-11
 
Eur J Gen Med 2011;8(1):53–56
KEYWORDS:
ABSTRACT:
Aim: Colorectal cancer patients are treated with surgery and sometimes radiotherapy and chemotherapy. Transforming growth factor beta-1 (TGF-β1) acts both as an inhibitor of tumor growth and as a promoter of tumor progression. The aim of this study was to determine the levels of TGF-β1 in plasma in colorectal cancer patients and relate these to the effect of clinicopathological variables. Method: One hundred patients scheduled for colorectal cancer surgery were included. Blood samples were taken during surgery and later assayed with enzyme linked immunsorbent assay for total TGF-β1 and active TGF-β1. Result: Total and active TGF-β1 was higher in tumor samples compared to controls (p<0.001).Total TGF-β1 was higher in patients with metastases compared to patients without. Active TGF-β1 levels were not found statistically different in patients with metastases.. Conclusion: Higher levels of total TGF-β1 in plasma at surgery may be indicate of distant metastases, Measurement of total TGF-β1 in colorectal cancer patients may be of clinical use in the future.
CORRESPONDING AUTHOR:
Özgür Kemik   
Department of General Surgery, Yuzuncu Yıl University Medical faculty, Van, Turkey
eISSN:2516-3507